Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports

Big Pharma player Eli Lilly is reportedly close to snapping up gene-editing startup Verve Therapeutics for a whopping $1.3 billion, according to the Financial Times. If the deal goes through, it would give Lilly a foothold in the cutting-edge world of genetic medicine—specifically, Verve’s work on CRISPR-based treatments for heart disease.